Related Experiment Video
Updated: Jun 19, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
KIT as a therapeutic target in melanoma
Maria C Garrido1, Boris C Bastian
1Department of Dermatology and UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, USA.
None:
Recently, genetic alterations activating the receptor tyrosine kinase KIT have been shown in some types of melanoma. KIT mutations can be successfully targeted by approved drugs in other cancers. Emerging evidence suggests that melanomas with KIT activation may also respond to KIT inhibitors that are already in clinical use. If confirmed in ongoing clinical trials, this experience would underscore the importance of recognizing the biological diversity among melanomas, representing a first decisive step toward the individualized and mechanism-based treatment of melanoma.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Tumor Immunotherapy
Inhibition of Cdk Activity
Mitogens and the Cell Cycle

